All posts by medical

Cover Coronavirus Outbreak: NEUROSCIENCE ANTIBODIES AND ASSAYS Market Statistics and Research Analysis Released in Latest Report Cole Reports – Cole…

The NEUROSCIENCE ANTIBODIES AND ASSAYS report provides independent information about the NEUROSCIENCE ANTIBODIES AND ASSAYS industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

NEUROSCIENCE ANTIBODIES AND ASSAYS MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of NEUROSCIENCE ANTIBODIES AND ASSAYS Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of NEUROSCIENCE ANTIBODIES AND ASSAYS Market: Products in the NEUROSCIENCE ANTIBODIES AND ASSAYS classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Company I, Company II, Company III, Company IV, Company V

NEUROSCIENCE ANTIBODIES AND ASSAYS Market Report Covers the Following Segments:

Segment by Type:

Type I

Type II

Type III

Segment by Application:

ApplicationI

Application II

Application III

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global NEUROSCIENCE ANTIBODIES AND ASSAYS Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide NEUROSCIENCE ANTIBODIES AND ASSAYS Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global NEUROSCIENCE ANTIBODIES AND ASSAYS Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global NEUROSCIENCE ANTIBODIES AND ASSAYS Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global NEUROSCIENCE ANTIBODIES AND ASSAYS Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global NEUROSCIENCE ANTIBODIES AND ASSAYS Market.

Market Forecast:Here, the report offers a complete forecast of the global NEUROSCIENCE ANTIBODIES AND ASSAYS Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/at-2101-cagr-3d-printing-market-size-to-surpass-usd-3903-billion-by-2025-2020-05-01

https://www.marketwatch.com/press-release/ride-hailing-market-is-expected-to-grow-at-usd-260-billion-by-2024-size-share-global-industry-report-2020-05-01

https://www.marketwatch.com/press-release/first-aid-kits-market-2020-industry-analysis-size-growth-share-trends-opportunity-and-forecast-to-2025-2020-04-30

Go here to see the original:
Cover Coronavirus Outbreak: NEUROSCIENCE ANTIBODIES AND ASSAYS Market Statistics and Research Analysis Released in Latest Report Cole Reports - Cole...

Subset of Retinal Neurons Communicates Differently From the Rest of the Eye – Technology Networks

The eyes have a surprise.

For decades, biology textbooks have stated that eyes communicate with the brain exclusively through one type of signaling pathway. But a new discovery shows that some retinal neurons take a road less traveled.

New research, led by Northwestern University, has found that a subset of retinal neurons sends inhibitory signals to the brain. Before, researchers believed the eye only sends excitatory signals. (Simply put: Excitatory signaling makes neurons to fire more; inhibitory signaling makes neurons to fire less.)

The Northwestern researchers also found that this subset of retinal neurons is involved in subconscious behaviors, such as synchronization of circadian rhythms to light/dark cycles and pupil constriction to intense bright lights. By better understanding how these neurons function, researchers can explore new pathways by which light influences our behavior.

"These inhibitory signals prevent our circadian clock from resetting to dim light and prevent pupil constriction in low light, both of which are adaptive for proper vision and daily function," said Northwestern's Tiffany Schmidt, who led the research. "We think that our results provide a mechanism for understanding why our eye is so exquisitely sensitive to light, but our subconscious behaviors are comparatively insensitive to light."

The research will be published in the May 1 issue of the journal Science.

Schmidt is an assistant professor of neurobiology at Northwestern's Weinberg College of Arts and Sciences. Takuma Sonoda, a former Ph.D. student in the Northwestern University Interdepartmental Neuroscience program, is the paper's first author.

To conduct the study, Schmidt and her team blocked the retinal neurons responsible for inhibitory signaling in a mouse model. When this signal was blocked, dim light was more effective at shifting the mice's circadian rhythms.

"This suggests that there is a signal from the eye that actively inhibits circadian rhythms realignment when environmental light changes, which was unexpected," Schmidt said. "This makes some sense, however, because you do not want to adjust your body's entire clock for minor perturbations in the environmental light/dark cycle, you only want this massive adjustment to take place if the change in lighting is robust."

Schmidt's team also found that, when the inhibitory signals from the eye were blocked, mice's pupils were much more sensitive to light.

"Our working hypothesis is that this mechanism keeps pupils from constricting in very low light," Sonoda said. "This increases the amount of light hitting your retina, and makes it easier to see in low light conditions. This mechanism explains, in least part, why your pupils avoid constricting until bright light intensifies."

Reference:

Takuma Sonoda, Jennifer Y. Li, Nikolas W. Hayes, Jonathan C. Chan, Yudai Okabe, Stephane Belin, Homaira Nawabi, Tiffany M. Schmidt. A non-canonical inhibitory circuit dampens behavioral sensitivity to light. Science, 2020 DOI: 10.1126/science.aay3152

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

The rest is here:
Subset of Retinal Neurons Communicates Differently From the Rest of the Eye - Technology Networks

Covid-19 has shuttered labs. It could put a generation of researchers at risk – STAT

Scientists are skilled at tackling unexpected problems that threaten the integrity of their experiments it comes with the territory. But the coronavirus pandemic poses a new and entirely unprecedented challenge.

The global health emergency has shut down scientific research labs across the country in a crisis that has left some scientists scrambling to save their work and has left others grieving the loss of experiments they had dedicated months or even years to carrying out. Many are grappling with an overwhelming sense of uncertainty about how theyll continue their work.

The situation has hit early-career researchers particularly hard. Their funding and their futures depend on quickly gathering data to publish in prestigious journals. Without additional financial support and an extension of tenure clocks, some scientists who have just started their own labs fear the delays to their studies may be too disruptive to overcome.

advertisement

Early-career scientists will be very vulnerable, said Cullen Taniguchi, assistant professor at University of Texas MD Anderson Cancer Center. Taniguchi said it will be crucial to properly support researchers when labs reopen or, he warned, we may lose a whole generation of researchers because of this.

Despite these struggles, many researchers say that shutting down the labs was necessary to stem the spread of the virus. And some labs are still up and running, though not all are doing so at full capacity. But for scientists whose work has been deferred, the closures have fueled a devastating ripple effect of consequences, both big and small.

advertisement

Even when laboratories are reopened, it may take months to a year for research to resume as normal.

I have [new hires] in the lab that havent even met each other physically, said Alice Soragni, a cancer researcher and assistant professor who runs a lab at the University of California, Los Angeles. There is a lot of training that needs to have happened that hasnt happened, she added.

STAT spoke to scientists across the country to better understand the wide-ranging impacts of lab shutdowns.

Scientists have transitioned from long hours in the laboratory to working from home but the abrupt halt to their research projects has left a lingering sense of disorientation for researchers like Kathleen Beeson, a sixth-year graduate student at Oregon Health and Science University.

Like many of her colleagues, Beeson was caught off guard by her labs closure.

We were given a weeks notice,she said. Immediately, I and others were in a race to finish experiments, collect any data that we could, and get the lab prepared for a minimum of six weeks of shutdown.

Beeson had been completing a final experiment for a publication she needs to earn her Ph.D. and move onto a postdoc research position at Harvard Medical School.

The shutdown has upended Beesons research, which involves measuring electrical activity in the brains of genetically engineered mice. Her work aims to describe how proteins at the junction of nerve cells help transmit chemical signals an important step in understanding neurological dysfunctions such as epilepsy.

While other scientists were able to freeze cells or preserve tissue samples in formaldehyde, Beesons research relied on analyzing freshly dissected brain tissue. Because she could no longer come into the lab, she had to sacrifice most of her mouse colony, which she had painstakingly raised from one male and one female to approximately 200 animals.

In the end, I found myself euthanizing mice by the masses in the university basement, she said. It was the punctuation on a sad and disorienting week.

Beeson said it will likely take her months to raise enough animals for experiments again. In the meantime, she has been working on her Ph.D. dissertation and a second publication from home although not at the pace that she had hoped for.

I applaud anyone making any progress, on anything, during this time, she said. Sometimes my progress is processing my grief.

Disruptions to research and long startup times pose an especially daunting challenge to early-career scientists who have just a few years to establish themselves as experts in their fields and obtain critical funding for their laboratories.

With experiments on hold, some early-career scientists cant collect the kind of preliminary data that is crucial for them to compete with more established researchers who have a decade or more of experimental findings to build on.

[All researchers] are impacted but I think there are exquisite challenges for early-career investigators like myself, said UCLAs Soragni.

To protect early-career scientists, the NIH has extended the time frame for which researchers can be considered early stage investigators a status that helps government institutes and centers prioritize funding for scientists running new laboratories. The agency has also relaxed some of the eligibility requirements for maintaining grants and added additional flexibility for spending funds.

Despite these welcome efforts, early-career researchers especially those lacking data needed to apply for new grants remain in a precarious position. Soragni and others said they hoped the NIH would take the impact of Covid-19 into account and temporarily adjust its criteria for reviewing applications. However, the agency has recommended that scientists without enough preliminary data submit their applications at a later date.

For Soragni, the most difficult challenge has been the uncertainty.

You are kind of left not knowing what you should do. Should you be ramping up completely? But what if you are switched down again?

Alice Soragni, UCLA cancer researcher

We really dont know if we are going to have a second wave of infections and what will be the consequences, she said. You are kind of left not knowing what you should do. Should you be ramping up completely? But what if you are switched down again? Should you be hiring? Will the economy bounce back? What is going to happen to your grants?

We are just at a more vulnerable stage of our career, Soragni said. I believe we may lose some laboratories to this, so that will be very painful to witness.

The shutdowns have taken a toll not only research, but also on the close professional relationships at the heart of scientific collaboration.

For Stephanie Campos, Covid-19 meant that she would not complete her research or be able to say goodbye to her mentor, Walter Wilczynski, in person. Campos had come to Georgia State University for a postdoctoral fellowship with Wilczynski, a pioneer in the field of behavioral neuroscience and the first director of the universitys Neuroscience Institute. But after 37 years of research, the lab was scheduled to close this summer after Wilczynskis cancer, once in remission, returned.

Campos and her colleagues were wrapping up their research a study of the brain activity in lizards aimed at unraveling the neural underpinnings of social behaviors when the pandemic hit. The lab shuttered earlier than expected.

With the laboratory closed, Campos has been limited to writing manuscripts from home and analyzing old videos of lizard behavior. She cant see Wilczynski who is immunocompromised again in person before she moves to a new role as a visiting assistant professor at Swarthmore College.

[This experience] has really affected me emotionally in the way that I knew I was going to be his last student, Campos said. And so I had really wanted to get as much as I could.

With Georgia easing restrictions on social distancing, there is a possibility that Campos could return to the lab late in the summer, but she is still unsure if returning to work would be socially responsible. Instead, she is planning on mailing the bulk of her delayed research project which involves 68 lizard brains preserved in vials of paraformaldehyde to Pennsylvania, where she will begin work in August.

Campos credits Wilczynski, who was at times too fatigued to read papers, for guiding her through the gauntlet of an academic job search and giving her the confidence to continue in academia.

His kindness during this time is what Ill remember the most, Campos said. For me it is all about the personal connection, how well your mentors make you feel. Those are the things that I will take away.

Waiting for their labs to reopen, principal investigators are steeling themselves for the months of effort that will be needed to reestablish the rhythms of a productive laboratory.

Theres a mountain of work to muddle through before experiments can get off the ground again.

We will have to first retest [our equipment] to make sure it is working, regrow our [bacterial] cultures, which takes a while, before we can even consider doing an experiment, said Eric Rubin, an immunology and infectious diseases researcher and professor at the Harvard T.H. Chan School of Public Health. Rubin also the editor-in-chief the New England Journal of Medicine.

Regrowing bacteria in Rubins laboratory is not a job for the impatient. The focus of his studies, Mycobacterium tuberculosis, causes tuberculosis and kills more people worldwide than any other infectious pathogen. M. tuberculosis also grows approximately 50 times more slowly than other microorganisms. Experiments that would take a day with other commonly studied bacteria typically take weeks in the Rubin lab.

When laboratories closed, Rubins team was in the midst of testing a batch of promising drug compounds for the ability to kill the bacteria. To resume the study, researchers will have to thaw out stocks of frozen bacteria and coax them to replicate in liquid broth.

We normally always have things growing so that we can grab them and do our next experiment, said Rubin. [But now] it will likely take four months before we will have enough cells to do experiments at full tilt again.

Restarting research may take even longer up to a year for those working with laboratory animals, such as Subhash Kulkarni, a scientist and assistant professor at Johns Hopkins University School of Medicine.

In 2017, Kulkarni showed that, contrary to established dogma, nerve cells lining the intestines continue to grow and divide in adult animals. To understand how this discovery could lead to new treatments for digestive disorders, Kulkarni had begun analyzing how neurons behaved over the lifespan of a mouse. This project required raising genetically engineered mice at staggered times to have enough of each age group at the start of the study.

With his lab closed, the entire effort will have to be repeated once Kulkarni is allowed to work again. That timeline is daunting.

Think of this as the time when the planets are in perfect alignment, Kulkarni said. Once that time is lost, making the next time requires [new] breedings, which can take anywhere from six to 12 months.

Original post:
Covid-19 has shuttered labs. It could put a generation of researchers at risk - STAT

Wider cost-benefit analysis will determine if WFH is a success – Livemint

NEW DELHI :The bandwagon of opinion that work-from-home is the amrit (nectar of immortality) that the covid manthan (churning) has yielded is growing and speeding down an implementation path that is long on profit-and-loss benefit and short on people-centricity. Corporates love the cost savings, but a fuller analysis will show that it is a double-edged sword to be handled with care, quickly accruing quantifiable savings for companies, but risking slowly accumulating costs for employees and organizations, perhaps not quantifiable early on but not un-measurable. Implement work from home (WFH) by all means, but after data-driven weighing of costs and benefits all around. We would like to see an equivalent level of discussion on the people dimension as we are seeing on cost savings.

Decision-makers, likely older, with older children, better paid, hence living in larger houses with better quality household help, are deciding on WFH from their own contexts, oblivious of employee contexts of smaller homes shared by more family members now also having to double as work spaces, small children demanding attention when they see a parent, and lower quality household help. As for it being a working womans dream, ask them and you will find not all women can manage expected productivity and WFHdisturbing her is the default option if she is at home (surprising how problems resolve themselves when you are at the office !)

People-centricity requires data from the other side and acceptance that there are segments and, so, a one-size policy doesnt fit all. Implicitly assuming that something is workable because it works for the five people who said it to me, or for the mancom, or even worse, that if it has worked in crisis times, it must work all the time, is irresponsible.

So, before jumping to the WFH saves rental cost and delights employees" conclusion and rushing to implement, we suggest a pause to get data on peoples home environments, family demographics, the pain points of WFH and, even more simply, an anonymous employee vote on the matter. Also needed is for HR to develop sound conceptual models on what improves or hampers WFH productivity based on the nature of work of employees in different grades and in different roles and to devise a whole new way of managing productivity.

Neuroscience shows that the chemical balance of the brain shifts when in isolation leading to lower feelings of psychological safety, affecting creativity and openness to change. Social interactions have more to them than video meeting the way they are currently done. Neuroscience theory of mirror neurons" suggests positive benefits of social interaction for teamwork, another holy grail of business leaders (The Star Factor, William Seidman et al and The Tell Tale Brain, V.S. Ramachandran).

Finally, it is also a business leaders responsibility to think about the implicit contract that employers have with employees to provide a work place" that is geared to work needs" (where you do not do meetings with your spouse, mother-in-law or toddler in attendance ). Also, work identity" is a very strong builder of self esteem and social standing, especially in India. Thats why money was spent in the first place on well-designed offices in specific locations that people feel proud to go to. WFH takes these away. Signalling caring for employees cannot be done while ignoring what WFH of the chief wage-earner does to the very structure of the family dynamics.

Rama Bijapurkar is an independent market strategy consultant, and Smita Affinwalla is founder of Illuminos HR Consulting.

Read more:
Wider cost-benefit analysis will determine if WFH is a success - Livemint

Students respond to lack of learning experiences – UWEC Spectator

In addition to face-to-face instruction at UW-Eau Claire, most internships have been discontinued for the spring semester due to the COVID-19 pandemic.

Now, students struggle to find new experiential opportunities for the summer.

Savana Stahl, a fourth-year social work student, said she learned a lot from her internship at Mayo Clinic before it was canceled in March.

I was really excited to learn more about the medical side of social work, Stahl said. I worked with different patients every day and learned a ton about the paperwork that goes into hospital visits, which is something a lot of people overlook.

Stahl said she had a couple of weeks left at her internship, but Mayo Clinic decided to cancel all of their internships before UW-Eau Claire pulled interns out of their sites.

We thought we were prepared before, but nobody anticipated as large of a pandemic as it ended up being, Stahl said.

Stahl said she was stressed to find alternate internships. The university social work department was able to help her find an opportunity with Feed My People food bank that later offered her a temporary job, she said.

I worked there for less than two weeks as an intern and then the university canceled all internships on their end, Stahl said. Now I am only a temporary employee until the end of May.

Stahl said she was excited to get the opportunity to go back and provide her help by doing modified field activities.

Catey Leonardson, a fourth-year English rhetoric student, had a technical writing internship on campus that also got discontinued due to COVID-19.

Initially I kept going to campus, because I was told we had the option to, Leonardson said. Then, I made the decision myself not to go anymore for safety and health reasons.

Leonardson said she is doing some of the work remotely and still getting income. However, she is frustrated to not receive the technical writing experience that she needs before graduation.

I was planning on finding a job and moving away from Eau Claire this summer, Leonardson said. But its really difficult, given the current situation.

Gorana Puzovic, a first-year neuroscience student from Serbia, joined a research project in crystallography back in February. She was assigned to work on the project this semester and continue throughout the summer.

We were supposed to do most of our research this summer and get trained on how to use some of the lab equipment, Puzovic said. Now it is postponed until we can go back to campus.

Puzovic said her research group still holds weekly meetings online, but even with those meetings, she has lost valuable time and the opportunity to learn something completely different from her current field of study.

Going into college, I was debating whether to pursue a major in chemistry or neuroscience, Puzovic said. This could have been an opportunity to potentially switch my major.

Puzovic said she is going to stay in the U.S. until she can go back to campus to work on the research project or until it is safe to fly back home.

Stahl said the support from the UW-Eau Claire social work department has been very impactful and her professors are making sure students have the resources they need.

Professors have been working with me and my peers individually, Stahl said. It is comforting to know that they really care about me as a person, not just a student.

Stahl said this semester has been an important learning experience and has learned that she has more support than she thought.

We are all in different situations, but we are all in this together, she said.

Klavina can be reached at [emailprotected].

See the article here:
Students respond to lack of learning experiences - UWEC Spectator

COVID-19 Progression May Be Impacted by Immune Response Timing – Technology Networks

A new USC study suggests that temporarily suppressing the bodys immune system during the early stages of COVID-19 could help a patient avoid severe symptoms.Thats because the research, published online in the Journal of Medical Virology, shows that an interaction between the bodys two main lines of defense may be causing the immune system to go into overdrive in some patients.

The bodys first line of defense, the innate immune response, starts right after an infection, like an infantry going after a foreign invader, killing the virus and any cells damaged by it. The second line of defense, the adaptive immune response, kicks in days later if any virus remains, employing what it has learned about the virus to mobilize a variety of special forces such as T cells and B cells.

Using the target cell-limited model, a common mathematical model developed to understand the dynamics of viral infections, the researchers examined how the two immune responses work in COVID-19 patients compared to patients who have the flu.

The flu is a fast-moving infection that attacks certain target cells on the surface of the upper respiratory system and kills almost all of the target cells within two to three days. The death of these cells deprives the virus of more targets to infect and allows the innate immune response time to clear the body of almost all of the virus before the adaptive system comes into play.

The danger is, as the infection keeps going on, it will mobilize the whole of the adaptive immune response with its multiple layers, said Weiming Yuan, associate professor in the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC, and co-corresponding author of the study. This longer duration of viral activity may lead to an overreaction of the immune system, called a cytokine storm, which kills healthy cells, causing tissue damage.

The interaction of the innate and the adaptive immune responses might also explain why some COVID-19 patients experience two waves of the disease, appearing to get better before eventually getting much worse.

Some COVID-19 patients may experience a resurgence of the disease after an apparent easing of symptoms, said Sean Du, adjunct researcher and lead author of the study. Its possible that the combined effect of the adaptive and the innate immune responses may reduce the virus to a low level temporarily. However, if the virus is not completely cleared, and the target cells regenerate, the virus can take hold again and reach another peak.

Based on the results of the mathematical modeling, we proposed a counterintuitive idea that a short regimen of a proper immunosuppressant drug applied early in the disease process may improve a patients outcome, said Du. With the right suppressive agent, we may be able to delay the adaptive immune response and prevent it from interfering with the innate immune response, which enables faster elimination of the virus and the infected cells.

Small studies out of China, including a recent one of COVID-19 patients and one of SARS patients in 2003 show patients who received immunosuppressants such as corticosteroids had better results than those who did not.

The researchers said a possible next step could be to take daily measurements of viral loads and other biomarkers in COVID-19 patients, to see if the data validates the mathematical modeling. More preclinical studies including experiments in animal models will also be needed to prove the efficacy of an early immune suppressing treatment.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

View post:
COVID-19 Progression May Be Impacted by Immune Response Timing - Technology Networks

Asthma and COPD Medication Adherence Has Increased During the COVID-19 Pandemic – Benzinga

Study in The Journal of Allergy and Clinical Immunology: In Practice, an official journal of the AAAAI, examines adherence trends before and during the outbreak of COVID-19 in the United States using data from Propeller Health's digital health platform.

MILWAUKEE (PRWEB) May 04, 2020

According to research from The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), controller inhaler adherence increased between January and March 2020, in the midst of the COVID-19 pandemic.

Researchers analyzed the adherence of controller inhaler use for 7,578 patients using Propeller Health, a digital platform that uses electronic medication monitors to track inhaler use and send alerts to patients about missed doses. Data showed that between the first seven days of January 2020 and the last seven days of March 2020, there was a 14.5% relative increase in mean daily controller medication adherence. During the last week of March, data showed over 53% of patients achieved 75% or greater medication adherence, up 14.9% from the first seven days of January.

"We are encouraged by the increase in patient adherence to their medications for asthma and COPD, which is critical to avoiding symptoms and keeping patients out of the hospital during this pandemic," said first author Leanne Kaye, PhD, MPH. "This research further supports that digital health tools can improve adherence and provide insight into patient well-being between office visits."

The study authors believe that the observed trend may be attributable to the ongoing COVID-19 pandemic guidelines regarding medication use, as well as patients' desire to keep their pre-existing respiratory disease under control at this time.

Daily controller medications are essential for patients with respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), especially during the COVID-19 pandemic. Controlling primary respiratory diseases with proper medication use can improve disease outcomes and reduce acute events requiring medical care, which could inadvertently expose a patient to COVID-19.

There were no statistically significant differences in improved medication adherence between asthma and COPD patients during the study period. The data showed similar medication adherence increases across all age groups, with older patients overall showing a higher baseline adherence.

You can learn more about asthma and COVID-19 on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI's Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

###

For the original version on PRWeb visit: https://www.prweb.com/releases/asthma_and_copd_medication_adherence_has_increased_during_the_covid_19_pandemic/prweb17086711.htm

Read the original post:
Asthma and COPD Medication Adherence Has Increased During the COVID-19 Pandemic - Benzinga

T Cell Counts and Cytokine Storms May Hold Key to Effective COVID-19 Treatment – Technology Networks

Cytokine storms may affect the severity of COVID-19 cases by lowering T cell counts, according to a new study published in Frontiers in Immunology. Researchers studying coronavirus cases in China found that sick patients had a significantly low number of T cells, a type of white blood cell that plays a crucial role in immune response, and that T cell counts were negatively correlated with case severity.Interestingly, they also found a high concentration of cytokines, a protein that normally helps fight off infection. Too many cytokines can trigger an excessive inflammatory response known as a cytokine storm, which causes the proteins to attack healthy cells. The study suggests that coronavirus does not attack T cells directly, but rather triggers the cytokine release, which then drives the depletion and exhaustion of T cells.

The findings offer clues on how to target treatment for COVID-19, which has become a worldwide pandemic and a widespread threat to human health in the past few months. We should pay more attention to T cell counts and their function, rather than respiratory function of patients, says author Dr. Yongwen Chen of Third Military Medical University in China, adding that more urgent, early intervention may be required in patients with low T lymphocyte counts.

Chen says he and his co-authors became interested in examining T cells when they noticed that many of the patients they treated for COVID-19 had abnormally low numbers of lymphocytes, a type of white blood cell that includes T cells. Considering T cells central role of response against viral infections, especially in the early stage when antibodies are not boosted yet, we took the T cells as our focal point, says Chen.

Authors examined 522 patients with coronavirus along with 40 healthy controls. All patients studied were admitted to two hospitals in Wuhan, China between December 2019 and January 2020, and ages ranged between 5 days and 97 years old. Of the 499 patients who had their lymphocytes recorded, 76% had significantly low total T cell counts. ICU patients had significantly lower T cell counts compared with non-ICU cases, and patients over the age of 60 had the lowest number of T cells.

Importantly, the T cells that did survive were exhausted and could not function at full capacity. Not only does this have implications for COVID-19 patient outcomes, but T cell exhaustion leaves patients more vulnerable to secondary infection and calls for scrupulous care.

Chen says that future research should focus on finding finer subpopulations of T cells in order to discover their vulnerability and effect in disease, along with identifying drugs that recover T cell numbers and boost function. Authors say that Tocilizumab is an existing drug that may be effective, but that it needs to be investigated in the context of coronavirus. Antiviral treatments, such as Remdesivir, may also prevent the progression of T cell exhaustion, but all future treatments will require further study.

In the meantime, this new research deepens our understanding of how the novel coronavirus affects the body and it indicates ways to lessen its impact.ReferenceDiao et al. (2020). Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Frontiers in Immunology. DOI: https://doi.org/10.3389/fimmu.2020.00827

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Follow this link:
T Cell Counts and Cytokine Storms May Hold Key to Effective COVID-19 Treatment - Technology Networks

Sitting on a Pile of Cash? Here is a Company in the Immunology Field with a 77% Upside Target Mid-term – Live Trading News

$CGEN

Compugen Ltd. (NASDAQ:CGEN) is seen as Buy and the price target at 23.

The stock finished at 13.82-0.70 (-4.82%) at close: 4:00p EDT and 13.90+0.08 (0.58%) Pre-Market:5:12a EDT

All of our Key indicators have turned Very Bullish across the board since 16 April. Key Support is at 11.79 and the Resistance is Nil.

Compugen Ltd. is a therapeutic discovery company engaged in the research, development, and commercialization of therapeutic and product candidates in Israel, the US, and EU.

The companys therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target.

Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program.

Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY)to evaluate the safety of COM701 in combination with Bristol-Myers Squibbs programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products.

The company was incorporated in Y 1993 and is HQd in Holon, Israel.

Have a healthy day, Keep the Faith!

BMY, CGEN, commercialization, development, discovery, immunology, oncology, product, research, therapeutic

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Go here to see the original:
Sitting on a Pile of Cash? Here is a Company in the Immunology Field with a 77% Upside Target Mid-term - Live Trading News

South Africa’s Covid-19 epidemic is almost only getting started – NICD expert – CapeTalk

Vaccine and immunology expert Dr Melinda Suchard says the number of Covid-19 infections in the country is only going to get higher.

Dr Suchard is the head of the Centre for Vaccines and Immunology at the National Institute for Communicable Diseases (NICD).

She says the Covid-19 numbers will rise as the country gradually eases the lockdown, with new transmission patterns expected to emerge.

Dr Suchard says the health system is still managing with sufficient bed capacity for infected patients so far.

RELATED: Dr Max Price explores reasons why SA has an extremely low Covid-19 death rate

The contact patterns are increasing.

We have to anticipate and expect higher numbers.

The numbers will go higher. We know that our epidemic is almost only getting started... The early lockdown prevented the numbers from taking off.

Listen to the discussion on Afternoon Drive with John Maytham:

Read the original here:
South Africa's Covid-19 epidemic is almost only getting started - NICD expert - CapeTalk